Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Details 詳細情報について

• CRID

  1361137045114718464

• DOI

  10.1016/j.ijid.2020.11.142

• ISSN

  12019712

• Web Site

  https://api.elsevier.com/content/article/PII:S120197122032453X?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S120197122032453X?httpAccept=text/plain

• Data Source

  • Crossref